Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Indaptus Therapeutics, Inc. (INDP) had Consolidated Net Income/Loss of $-2.98M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-2.98M |
|
-- |
|
-- |
|
$2.65M |
|
$-2.65M |
|
$-0.33M |
|
$-2.98M |
|
$-2.98M |
|
$-2.98M |
|
$-2.98M |
|
|
Consolidated Net Income/Loss |
$-2.98M |
$-2.98M |
|
$-2.65M |
|
$-2.65M |
|
1.00M |
|
1.00M |
|
$-2.98 |
|
$-2.98 |
|
| Balance Sheet Financials | |
$6.44M |
|
-- |
|
$0.40M |
|
$6.84M |
|
$2.23M |
|
-- |
|
-- |
|
$2.23M |
|
$4.61M |
|
$4.61M |
|
$4.61M |
|
1.64M |
|
| Cash Flow Statement Financials | |
$-11.63M |
|
-- |
|
$11.67M |
|
$5.79M |
|
$5.83M |
|
$0.04M |
|
$0.57M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.88 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-11.63M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-64.60% |
|
-64.60% |
|
-43.50% |
|
-64.60% |
|
$2.81 |
|
$-11.67 |
|
$-11.67 |
|